To the full analysis
Buyback calculator for Samsung Biologics
Samsung Biologics stock: dividend
207940.KSSamsung Biologics does not currently pay a dividend. From fiscal 2023 to 2025, Samsung Biologics bought back its own shares for $68.97M.
Whether Samsung Biologics Co.,Ltd. pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 13 Nov 2026
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | $641.68M | $68.97M | 46.24M |
| 2024 | $211.18M | $0 | 46.29M |
| 2023 | $420.44M | $0 | 46.29M |
| 2022 | −$42.11M | $0 | 45.36M |
| 2021 | $25.07M | $0 | 43.49M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₩1,334.10)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.